Clinical Course of Relapsing Remitting Multiple Sclerosis Post-Natalizumab

Maximillian D.J. Fiander, Virender Bhan, Samuel A. Stewart, Natalie E. Parks

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

1 Cita (Scopus)

Resumen

Natalizumab is an efficacious disease modifying therapy (DMT) for relapsing remitting multiple sclerosis (RRMS), often limited by risk of progressive multifocal leukoencephalopathy. We describe the clinical course of RRMS patients switched from natalizumab to another DMT. We identified all RRMS patients treated with natalizumab ≥3 months with JC virus antibody positivity who switched to another DMT. Overall, 84 individuals switched DMT with 57 (68%) beginning fingolimod. On fingolimod, survival without a relapse was 74% (55.8-85.6%) at 36 months and survival without disease progression was 78% (62.6-87.6%) at 36 months. In conclusion, fingolimod is an effective therapy post-natalizumab.

Idioma originalEnglish
Páginas (desde-hasta)455-458
Número de páginas4
PublicaciónCanadian Journal of Neurological Sciences
Volumen46
N.º4
DOI
EstadoPublished - jul. 1 2019

Nota bibliográfica

Publisher Copyright:
© 2019 The Canadian Journal of Neurological Sciences Inc.

ASJC Scopus Subject Areas

  • Neurology
  • Clinical Neurology

PubMed: MeSH publication types

  • Journal Article

Huella

Profundice en los temas de investigación de 'Clinical Course of Relapsing Remitting Multiple Sclerosis Post-Natalizumab'. En conjunto forman una huella única.

Citar esto